Abbott expands post-launch DES trial, adding to research on blood thinners
This article was originally published in Clinica
Executive Summary
The post-approval study of Xience V, Abbott's US market-leading drug-eluting stent (DES) has been expanded to include a further 3,000 patients. The expansion will allow greater understanding of the use of antiplatelet therapy.